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Ovarian cancer is the seventh most common cancer and
the fifth leading cause of cancer death in the world,
after lung and bronchial cancers, and breast, colorectal
and pancreatic cancers. Ovarian cancer causes more
deaths than any other cancer of the female reproduc-
tive system. Brain metastases resulting from primary
ovarian cancer are uncommon [1]. However, recent
studies have suggested an increased incidence of brain
metastases in patients with primary ovarian cancer
[2–4]. Surgery, irradiation, and chemotherapy can all
be used to prolong patient survival, although the prog-
nosis remains poor [4]. McMeekin et al [5] studied the
survival of 104 ovarian cancer patients with metastatic
brain disease following a combination of surgery, irra-
diation, and/or chemotherapy. Their report indicated a
median survival of 6 months for these patients, regard-
less of the treatment modality [5]. Some investigators
have reported relatively successful efforts in prolong-
ing the life of these metastatic patients. Gabriele et al
reported a mean survival of 17 months in a group of
23 ovarian cancer patients with solitary brain metas-
tases treated with surgery and radiotherapy [6]. The
survival of ovarian cancer patients with metastatic dis-
ease treated with irradiation was around 2 years [5,7].
Systemic chemotherapy has also proven effective for
the treatment of brain metastases [1,7].
A 58-year-old Taiwanese woman was originally re-
ferred to our gynecologic oncology clinic for treatment
of an ovarian epithelial carcinoma in May 2005. She
presented with increased abdominal girth and poor
appetite. Her preoperative serum CA-125 level was
4,491 U/mL. She underwent laparotomy with optimal
debulking surgery (en bloc total abdominal hysterectomy
and bilateral salpingo-oophorectomy, and cavitron ul-
trasonic surgical aspirator debulking from the peritoneal
surfaces). The pathology revealed a poorly differentiated
stage IIIC ovarian serous adenocarcinoma (Figure 1) with
metastasis to the omentum, appendix, paraortic and
pelvic lymph nodes. The patient subsequently received
six courses of paclitaxel and carboplatin, commencing
in June 2005. Her CA-125 level fell to 12.7 U/mL in
November 2005, and complete clinical and surgical
remission was achieved. Another 12 courses of main-
tenance paclitaxel chemotherapy were administered
thereafter, and her serum CA-125 level ranged from 12
to 15 U/mL until November 2006. In May 2007, she
presented with intermittent headaches, nausea, cogni-
tive dysfunction, gait ataxia, and urinary and fecal
incontinence, resulting in consultation with a neurolo-
gist. There was no weakness, syncope or seizure history.
A brain magnetic resonance imaging examination re-
vealed a 5-cm mass in the left frontal lobe with a cystic
component and irregular thick wall, and perifocal edema
with compression of the left lateral ventricle, resulting
in midline structures shifting to the right side (Figure 2).
No other apparent lesions were noted in the abdomen,
chest or spine. An elevated serum CA-125 level, as high
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Figure 1. Pathologic report showed typical serous adenocar-
cinoma.
as 331 U/mL, was also noted. Our patient underwent
resection of the left frontal mass in May 2007. The
pathology revealed metastatic adenocarcinoma con-
sistent with the ovarian origin (Figure 3). She subse-
quently received adjuvant radiation therapy (5,000 cGy)
to the tumor bed in 25 fractions, using the three-
dimensional conformal technique, from June to August
2007, together with chemotherapy (carboplatin and
doxorubicin). A magnetic resonance imaging scan in
September 2007 was unremarkable, with no evidence of
recurrent malignancy (Figure 4). The patient’s serum
CA-125 remained normal, and she continued to be a
pleasant and active individual.
The cases of ovarian cancer with brain metastasis
reported in the English literature are summarized in
the Table. These cases had durable oncologic control;
however, the rarity of this entity means that no prospec-
tive randomized studies aimed at determining the stan-
dard of care are currently available.
The use of optimal cytoreductive surgery to treat
ovarian cancer that has developed into metastatic brain
disease is not common, although some reports have sug-
gested that its use may be increasing [2–4]. Few large-
scale studies, however, have addressed the question of
the best treatment strategy for these patients. Several
published reports demonstrated that aggressive treat-
ment might be effective in selected patients. The addi-
tion of radiation and chemotherapy to surgical resection
of solitary brain metastases has been associated with
durable control [1,4,7]. Rodriguez et al [8] reported a
median survival of 20 months using this multidiscipli-
nary approach. Surgery combined with cisplatin-based
chemotherapy and stereotactic radiotherapy may pro-
long patient survival even further. Patients with solitary
brain metastases are most likely to benefit from aggres-
sive multimodality treatment. Cormio et al [1] reported
a patient with grade IV ovarian carcinoma who devel-
oped brain metastases and survived for 30 months
following chemotherapy with carboplatin, before even-
tually succumbing to recurrent pelvic disease.
The hematologic and lymphatic systems both pro-
vide common routes for metastasis of primary ovarian
cancers to the brain. However, treatment does not differ-
entiate between these two routes of cancer dissemina-
tion into the central nervous system. The application of
chemotherapy to brain tumors has been limited by the
inability of most chemotherapeutic agents to penetrate
the blood–brain barrier. It has, however, been suggested
that doxorubicin is strong candidate for chemotherapy
of the central nervous system, because it is thought to
have the ability to cross the blood–brain barrier. We at-
tributed the isolated central nervous system metastasis
in our patient to the inability of the chemotherapeutic
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Figure 3. Histopathologic examination of the brain lesion
revealed similar morphology to that of the primary ovarian
serous adenocarcinoma.
Figure 4. Brain magnetic resonance image 4 months after
surgery showed no signs of recurrence. Some postoperative
changes with bone defects and tissue loss in the left anterior
frontal area were noted.
Figure 2. Solitary large tumor mass with irregular thick wall
and a mainly cystic component (maximum diameter, 55 mm)
was noted in the left frontal area and left frontal and ventricle
with overt perifocal edema and compression.
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agents used for her primary ovarian cancer to penetrate
the blood–brain barrier. A recent study reported the use
of intra-arterial chemotherapy with or without blood–
brain barrier disruption, and demonstrated excellent
outcomes in patients with ovarian cancer metastases
to the brain [9]. Many chemotherapeutic agents (e.g.
carboplatin) were unable to permeate the blood–brain
barrier, and were thus unable to protect patients from
the subsequent development of brain metastases [10].
The solitary brain metastasis in our patient may have
contributed to her relatively protracted survival, com-
pared with patients with multiple lesions [7].
Chen et al [11] investigated 19 cases of ovarian
carcinoma with brain metastases and concluded that
the Radiation Therapy Oncology Group recursive par-
titioning analysis prognostic classification system was
valid in this patient group. They also identified multi-
ple brain lesions and the absence of surgical resection
as the two main prognostic factors predictive of a poor
outcome.
In conclusion, recurrence of ovarian cancer in the
brain is an extremely rare event. Serum CA-125 measure-
ment has a poor predictive value for brain metastasis,
compared with other metastases. Diagnostic examina-
tions, such as computed tomography or magnetic reso-
nance imaging, are often not arranged until symptoms
develop. A standard management program for these
cases is yet to be determined, and the establishment of
multicenter collaborative studies is warranted. When
possible, aggressive treatment with surgery and/or irra-
diation therapy, as well as chemotherapy, is recom-
mended in this subgroup of patients with recurrent and
metastatic ovarian cancer.
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